[1] Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer. Retrieved December 10, 2021, from https://ir.arvinas.com/news-releases/news-release-details/arvinas...
[2]https://en.wikipedia.org/wiki/Antibody-drug_conjugate [3]Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279‐e289. doi:10.1016/S1470-2045(13)70567-9 [4]Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--improving the...
Prevention and treatment of metastatic breast cancer (BC) is an unmet clinical need. The retinoic acid derivative fenretinide (FeR) was previously evaluated in Phase I-III clinical trials but, despite its excellent tolerability and antitumor activity in preclinical models, showed limited therapeutic ...
《自然-通讯》本周发表的一项研究The prognostic effects of somatic mutations in ER-positive breast cancer指出,雌激素受体阳性乳腺癌患者体内三种罕见的基因突变会对疾病的预后产生不良影响。 突变复发和新的剪接位点突变。 雌激 2018-09-05 17:34 News WIKI 相关搜索 引发...
A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study: The purpose of this study is to test the safety and effectiveness of a sequence of drugs (a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Der...
by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer. Retrieved August 11, 2022 from https://www.menarini.com/en-us/news/news-detail/menarini-groups-elacestrant-granted-priority-review-by-the-us-fda-for-patients-with-erher2-advanced-or-metastatic-breast-cancer...
13、*rMmIKMnfMliiRfeWPwwfl訶7litt|FWSimMVryllMdtar理口K:1MMiMqiwwu*rMmIKMnfMliiRfeWNCCN昭岀inc各iMteETateWCnntEribDiicuww器需:=嘶NCCNGuidelinesVersion1.2021NCCN护呼invaSjveBreastCancerNetworkP皿Reciiin住前号f*Paclrtaiel*traujumab11-5i*TCH【如朝鸵叱n卿汕nJV禅個珂?/;|TCHP也凹更也追理Fngi...
Talzenna(talazoparib)上市,talazoparib ( Talzenna,Pfizer )用于治疗her 2阴性的局部晚期或转移性乳腺癌,这些乳腺癌带有种系BRCA ( gBRCA )突变。Talazoparib是辉瑞公司研发的PARP抑制剂也是迄今为止,FDA批准的第4款PARP抑制剂。▲Talazoparib分子结构(图片来源:By Ed (Edgar181) [Public domain], from Wiki...